1. All for One: Multidisciplinary Management in EGFR-Mutated NSCLC

3. This program will include a discussion of off-label treatment and investigational agents not approved by the FDA for use in the United States and data that were presented in abstract form. These data should be considered preliminary until published in a peer-reviewed journal.

4. Multidisciplinary Team Members

5. Communication During Treatment

6. Patient: Presentation

7. What Is the Best Approach for Biopsy in Lung Cancer?

8. Considerations for FNA

9. Optimizing Biopsies for Testing

10. Guidelines for Testing Newly Diagnosed Patients

11. Molecular Testing and Treatment

12. Patient: Front-Line Results

13. Front-Line TKIs in EGFR-Positive NSCLC

14. Traditional Roles for Palliative Radiation in Stage IV NSCLC

15. RT or TKI in EGFR-Positive NSCLC

16. Retrospective Analysis: RT vs TKI

17. Patient: Progression

18. Best Biopsy Site on Progression

19. Is a Biopsy Always Necessary?

20. Progression and Points of Failure

21. Patient: Test Results at Progression

22. Conclusion

23. Abbreviations

24. Abbreviations (cont)